Compare iShares Gold Trust (IAU) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Nuwellis Inc — how do they compare? iShares Gold Trust trades at $78.86 (market cap $61.51B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares Gold Trust is far larger — about 27959.1× Nuwellis Inc's market cap, and iShares Gold Trust is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Nuwellis Inc for 26 Days on average.
| IAU | NUWE | |
|---|---|---|
Market Cap | $61.51B | $2.20M |
Volume | 3,206,729 | 121,544 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $146.65 |
52-Week Low | $74.21 | $0.68 |
Typical Hold Time | 49 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.88, up 2.36% with a $1.82 daily gain, though technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, with support levels at $76-$77 and resistance at $78-$79. Recent news highlights gold's sensitivity to inflation data and interest rate expectations.
The outlook remains cautious due to macroeconomic headwinds and technical weakness. Investment opportunities exist if gold prices stabilize amid inflation concerns, but risks include persistent rate hikes and dollar strength. Monitor Fed policy and economic data for directional cues.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
